Tipping the health balance

Patients will be forced to seek out pain treatments with poorer safety profiles given the increased cost of Panadol Osteo, a leading consumer advocacy group claims.

Debate continues to rage about the cause and effect of the medicine’s rapid price hike after it was taken off the PBS on 1 January as part of the Federal Government’s PBS sustainability package.

The manufacturer of Panadol Osteo, GSK, requested the full removal of the drug from the PBS, the Department of Health claimed recently as the government faced